<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="691">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 29, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04363632</url>
  </required_header>
  <id_info>
    <org_study_id>ET20-069</org_study_id>
    <nct_id>NCT04363632</nct_id>
  </id_info>
  <brief_title>Prospective Analysis of Morbi-mortality of Patients With Cancers in Active Phase of Treatment Suspected or Diagnosed of a SARS-CoV-2 Infection</brief_title>
  <acronym>ONCOVID-19</acronym>
  <official_title>Prospective Analysis of Morbi-mortality of Patients With Cancers in Active Phase of Treatment Suspected or Diagnosed of a SARS-CoV-2 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Leon Berard</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      National multicentre epidemiological study to describe retrospectively and prospectively the
      clinical outcomes of patients with a suspected coronavirus infection (either confirmed or
      not) while receiving a medical treatment for the underlying cancer
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2, 2020</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>2 Months</target_duration>
  <primary_outcome>
    <measure>Mortality of cancer patients under active anticancer treatment</measure>
    <time_frame>2 months after the date of the diagnostic procedure</time_frame>
    <description>Mortality rate, defined as the proportion of patients who are dead 2 months after the date of the diagnostic procedure for the 2 cohorts of patients (positive and negative).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>6 months (i.e. at the the time of last patient last visit)</time_frame>
    <description>Overall survival will be defined as the time from the date of the first diagnostic procedure (either diagnostic test or chest imaging) to the date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations</measure>
    <time_frame>2 months after the date of the diagnostic procedure</time_frame>
    <description>The duration of hospitalization (from the date of hospitalization to the date of definitive discharge for live patients)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>6 months (i.e. at the the time of last patient last visit)</time_frame>
    <description>Cause of death, related or not to the COVID-19</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>2 months after the date of the diagnostic procedure</time_frame>
    <description>Associated complications described by their type</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations</measure>
    <time_frame>2 months after the date of the diagnostic procedure</time_frame>
    <description>proportion of hospitalizations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' characteristics</measure>
    <time_frame>At the date of the diagnostic procedure</time_frame>
    <description>To describe accurately patients' characteristics in terms of demographics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' characteristics</measure>
    <time_frame>At the date of the diagnostic procedure</time_frame>
    <description>To describe accurately patients' characteristics in type of tumor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' characteristics</measure>
    <time_frame>At the date of the diagnostic procedure</time_frame>
    <description>To describe accurately patients' characteristics in type of anticancer treatment,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' characteristics</measure>
    <time_frame>At the date of the diagnostic procedure</time_frame>
    <description>To describe accurately patients' characteristics in terms of comorbidities</description>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Sars-CoV2</condition>
  <condition>Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with cancer in active phase of treatment suspected or diagnosed of a SARS-CoV-2
        infection
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        I1. Confirmed diagnosis of any type of solid or hematologic tumor;

        I2. Ongoing anticancer treatment (cytotoxic, targeted therapy, immunotherapy or loco
        regional procedure, including radiotherapy, surgery or interventional radiology procedure)
        at the time of inclusion or within the last 3 months prior to inclusion (last treatment
        administration or last loco regional procedure) ;

        I3. Patient with suspicion of COVID-19 (clinical symptoms of COVID-19 including fever
        (&gt;38°C) and/or respiratory tract symptoms), either confirmed or not.

        Note 1: Patients must have underwent diagnostic procedures: diagnostic test (positive or
        negative) and/or chest imaging. Note 2: Patients will be eligible regardless of the
        presence of a neutropenia (either febrile or not) ;

        I4. Patient and/or family did not decline data collection after complete information.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Julien GAUTIER</last_name>
    <phone>+33 4.26.55.68.29</phone>
    <email>julien.gautier@lyon.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Souad ASSAAD, Dr</last_name>
    <phone>0478782641</phone>
    <email>Souad.ASSAAD@lyon.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon PERNOT, Dr.</last_name>
      <email>s.pernot@bordeaux.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne HAMON, Dr.</last_name>
      <email>m.hamon@baclesse.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Métropole Savoie</name>
      <address>
        <city>Chambéry</city>
        <zip>73011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jocelyne PROVENCAL, Dr.</last_name>
      <email>Jocelyne.Provencal@ch-metropole-savoie.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier DURANDO, Pr.</last_name>
      <email>xavier.durando@clermont.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Laure Anne-Laure, Dr.</last_name>
      <email>ALLamm@cgfl.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume Carbonnelle, Dr.</last_name>
      <email>g-carbonnelle@o-lambret.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Souad ASSAAD, Dr</last_name>
      <phone>0478782641</phone>
      <email>Souad.ASSAAD@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Annecy-Genevois</name>
      <address>
        <city>Metz-Tessy</city>
        <zip>74370</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laetitia STEFANI, Dr.</last_name>
      <email>lstefani@ch-annecygenevois.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte FAUCHER, Dr.</last_name>
      <email>Charlotte.faucher@icm.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groupement Hospitalier Porte de Provence</name>
      <address>
        <city>Montélimar</city>
        <zip>26216</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blaha BELGADI, Dr.</last_name>
      <email>blahabelgadi@yahoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas MARTIN, Dr</last_name>
      <email>Nicolas.MARTIN@nice.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon-Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien PERON, Dr.</last_name>
      <email>julien.peron@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51726</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yacine MERROUCHE, Dr.</last_name>
      <email>Yacine.MERROUCHE@reims.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane LEPRETRE, Dr.</last_name>
      <email>stephane.lepretre@chb.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magali BRIERE, Dr.</last_name>
      <email>Magali.briere@ico.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de cancérologie Strasbourg Europe (ICANS)</name>
      <address>
        <city>Strasbourg</city>
        <zip>67033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roland SCHOTT, Dr.</last_name>
      <email>r.schott@icans.eu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer de Toulouse - IUCT Oncopole</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre DELORD, Pr.</last_name>
      <email>delord.jean-pierre@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Valence</name>
      <address>
        <city>Valence</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique DRAMAIS, Dr.</last_name>
      <email>ddramais@ch-valence.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 23, 2020</study_first_submitted>
  <study_first_submitted_qc>April 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2020</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Oncology</keyword>
  <keyword>Epidemiology</keyword>
  <keyword>Predictive factors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

